Navigation Links
Anthera Announces Update Call Regarding Vial Problems
Date:12/9/2010

HAYWARD, Calif., Dec. 9, 2010 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced it will hold a conference call to provide an update on the ongoing investigation and remediation plans relating to vial problems in the PEARL-SC clinical study. Conference Call Access:Date:

December 14, 2010Time:

5:00 pm Eastern TimeDomestic Dial-in:

(877) 312-8807International Dial-in:

(253) 237-1190Conference ID:

29519371The slides associated with the call can be accessed by logging into the live webcast at www.anthera.com.

To access the 24-hour audio replay, U.S. and Canadian participants may dial (800) 642-1687; international participants may dial (706) 645-9291.  The conference ID for the replay is 29519371. The audio replay will be available until December 21, 2010.  This conference call will be webcast live and archived on Anthera's website until December 14, 2011, www.anthera.com.  

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. Anthera has one Phase 3 clinical program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease (CAD). Anthera's Phase 2 product candidate, A-623, targets elevated levels of B-lymphocyte stimulator, or BAFF, which has been associated with a variety of B-Cell mediated autoimmune diseases, including systemic lupus erythematosus, or lupus. For more information, please visit www.anthera.com.

CONTACT: Bianca Nery of Anthera Pharmaceuticals, Inc., bnery@anthera.com or 510-856-5586.


'/>"/>
SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Anthera Pharmaceuticals Reports 2010 Third Quarter Financial Results and Operational Update
2. Anthera Announces Third Quarter 2010 Financial Report and Conference Call
3. Anthera Pharmaceuticals Announces Pricing of $31.5 Million PIPE Financing
4. Anthera Pharmaceuticals to Present at Deutsche Bank Securities 35th Annual Health Care Conference
5. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
6. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
7. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
8. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
9. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
10. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
11. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... and Markets has announced the addition of the "South Korean Proton ... report to their offering. ... The South Korean Proton Therapy Market is expected to almost triple ... Therapy Market for South Korea was valued at ... plays an important role in delivering comprehensive cancer care to children and ...
(Date:3/29/2017)... 2017  Experts in the field in alcohol ... Soberlink Systems  as a model for recovery through ... early 2017, concluded that remote blood alcohol monitoring ... recovery." The findings of the expert ... detail a range of variables that are commonplace ...
(Date:3/29/2017)... , March 29, 2017 Optometrists have ... as the highest standard in quality and care ... introduces its objective Wavefront-driven refraction technologies and process ... This enables an unprecedented level of refraction and ... vision relegated to Topgun Navy fighter pilots, but ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... Full Contact K9, an Atlanta-based dog ... Protect Law that assists dog owners in creating legally-enforceable pet trusts for their ... the natural next step to protect their new companion. Says Evan Dunbar, CEO of ...
(Date:3/29/2017)... ... March 30, 2017 , ... Youth Futures International (YFI) premiered its Serve, ... high school and college students who have participated in the program every summer. ... is now accepting applications for enrollment. Visit http://www.ghana.yfiexperience.org to learn more. ...
(Date:3/29/2017)... ... March 29, 2017 , ... Wells ... for attending prescribers at the upcoming World Congress, in Hollywood Florida April 6-8, ... been recognized as the visionary leader in the training of physicians, scientists, and ...
(Date:3/29/2017)... ... March 29, 2017 , ... Based on research from Guardian’s ... face in trying to balance both short-term and long-term benefits demands. Are ... the growing complexity, companies are finding that the short-term strategies used to control ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... (GRMA) is growing as it continues developing an ANSI-approved, consensus-based American National ... organization, which plans to publish the first ANSI-approved GMP standard for dietary ...
Breaking Medicine News(10 mins):